Author

M. Ameratunga

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Assay:proteomics· 1

Frequent Co-Authors

M. Shackleton· 3 shared P. Zhao· 3 shared A. A. Antolin· 2 shared C. Huang· 2 shared F. Noguchi· 2 shared G. Kuser Abali· 2 shared I. Leece· 2 shared M. Andrews· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. Shackleton

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases

I. R. Walpole, F. Y. Zaman, P. Zhao, V. M. Marshall, F. P. Lin, D. M. Thomas, M. Shackleton, A. A. Antolin, M. Ameratunga

This paper presents a computational method to identify off-target drug binding interactions for oncology drug repurposing using pharmacological databases and clinical data.

bioRxiv · Jul 1, 2023Biochemistry

Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression via GTP

G. Kuser Abali, F. Noguchi, P. Szeto, Y. Zhang, C. Huang, C. K. Barlow, G. Pomilio, C. Chew, S. Masoumi Moghaddam, P. Zhao, M. Andrews, I. Leece, J. G. Cheung, M. Ameratunga, N. C. Wong, , M. Shackleton

This paper identifies a non-canonical, methyltransferase-independent mechanism by which EZH2 promotes melanoma progression through interactions with IMPDH2 and GTP synthesis.

bioRxiv · Nov 2, 2021 · PreprintCancer Biology

EZH2 Abundance Regulated by UHRF1/UBE2L6/UBR4 Ubiquitin System is the Potential Therapeutic Target to Trigger Pigmented Phenotype in Melanoma

G. Kuser Abali, Y. Zhang, P. Szeto, P. Zhao, S. Masoumi Moghaddam, I. Leece, C. Huang, J. Cheung, M. Ameratunga, F. Noguchi, M. Andrews, N. C. Wong, R. B. Schittenhelm, M. Shackleton

The paper identifies the UHRF1/UBE2L6/UBR4 ubiquitin system as a regulator of EZH2 abundance, which controls pigmentation in melanoma by influencing melanin biosynthesis.

bioRxiv · Mar 4, 2021 · PreprintCancer Biology

The off-target kinase landscape of clinical PARP inhibitors

A. A. Antolin, M. Ameratunga, U. Banerji, P. Clarke, P. Workman, B. Al-Lazikani

This study identifies the off-target kinase profiles of four FDA-approved PARP inhibitors, revealing unique polypharmacological effects with potential clinical implications.

bioRxiv · Jan 14, 2019Pharmacology & Toxicology